Pegloticase is safe and effective to treat patients with refractory gout who are undergoing dialysis, according to recently presented research.


Pegloticase is safe and effective to treat patients with refractory gout who are undergoing dialysis, according to recently presented research.

In 1888, Dr. Jan Mikulicz-Radecki reported a case of chronic, bilateral, painless enlargement of the salivary and lacrimal glands that appeared to be idiopathic.1 In subsequent years, other patients with these findings were reported, and the term Mikulicz syndrome was used to describe these cases. Although Mikulicz syndrome is now known to be associated with…

Some artists paint with oils or watercolors, others with acrylics. Shivani Garg, MD, MS, prefers Nescafé or Maxwell House coffee. A faculty member in the Division of Rheumatology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health (UWSMPH), Madison, Dr. Garg learned this technique—painting with instant coffee mixed…

In spring 2020, as it became obvious that COVID-19 wasn’t going anywhere anytime soon, the leaders of the Rheumatology Research Foundation implemented an expedited process to distribute research funding beyond its typical awards program. This resulted in the Foundation awarding $1.65 million to fund five research studies that will look at the relationships between rheumatic…

Manuel F. Ugarte-Gil, MD, MSc, & Graciela S. Alarcón, MD, MPH |
A 26-year-old Peruvian woman presented to the emergency department of a large teaching hospital in Lima, Peru, with epistaxis and hematomas that had occurred over the preceding few days; she was found to have severe thrombocytopenia and a normocytic, normochromic anemia. She was treated with pulse doses of methylprednisolone; however, within two days, she presented…

Mary Choy, PharmD, BCGP, FASHP |
More than 7 million doses of the Johnson & Johnson single-dose vaccine have been administered in the U.S.1 On Apr. 23, the Centers for Disease Control & Prevention (CDC) and the U.S. Food & Drug Administration (FDA) recommended lifting the recommended pause on Johnson & Johnson COVID-19 vaccine use following a thorough safety review. 2…

From ARP Representatives to the ACR Government Affairs Committee |
The Budget Control Act of 2011 cut Medicare physician payments by 2% across the board. The Coronavirus Aid, Relief, and Economic Security (CARES) Act, signed into law in 2020, suspended this sequester (i.e., a cut in government spending) between May 1 and Dec. 31, 2020. In the Consolidated Appropriations Act, signed into law in December…

Akrithi Udupa, MD, Paul McIntosh, MD, Thomas J. Cummings, MD, & Lisa Criscione-Schreiber, MD, Med |
Dermatomyositis is an uncommon autoimmune condition involving skeletal muscle characterized by subacute onset of progressive weakness, intramuscular inflammatory infiltrates and the presence of myositis-specific autoantibodies.1 Immune-mediated myopathies may exert some pathogenic effects on the muscle tissue by targeting the microvasculature.1 Capillary inflammation, fragility and loss may contribute to heightened bleeding events in these patients. Here,…

We know a large percentage of the U.S. population falls into a vaccine-hesitant group. In fact, only 60% of Americans plan to be vaccinated against COVID-19, according to an article in The Atlantic.1 Given that rheumatology patients are among the vulnerable, we asked a handful of ACR/ARP members whether they have been vaccinated themselves and…

A phase 3 trial described in The New England Journal of Medicine (NEJM) highlights the potential of a C5a receptor inhibitor, avacopan, for anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis.1 Avacopan may potentially offer a steroid-sparing option for the treatment of this serious disease. Current Treatment of ANCA-Associated Vasculitis Morbidity and mortality from ANCA-associated vasculitis have…